financetom
Business
financetom
/
Business
/
Market Chatter: Berkshire Hathaway Chair Buffett 'Disappointed' in Kraft Heinz Breakup
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Berkshire Hathaway Chair Buffett 'Disappointed' in Kraft Heinz Breakup
Sep 2, 2025 10:52 AM

01:26 PM EDT, 09/02/2025 (MT Newswires) -- Berkshire Hathaway ( BRK/A ) (BRK.A, BRK.B) Chairman and Chief Executive Warren Buffett is "disappointed" in the planned separation of Kraft Heinz ( KHC ) into two independent publicly traded companies, CNBC reported Tuesday.

Buffett said the merger he had masterminded was not a brilliant idea, but he does not think splitting Kraft Heinz ( KHC ) would fix its problems, the report said.

He said Greg Abel, who will take the helm at Berkshire Hathaway ( BRK/A ) at yearend, expressed disappointment to the packaged food company, according to the CNBC report.

A Berkshire Hathaway ( BRK/A ) spokesperson confirmed the report's accuracy, Bloomberg reported.

Berkshire Hathaway ( BRK/A ) and Kraft Heinz ( KHC ) did not immediately respond to requests for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ocular Therapeutix Receives Special Protocol Assessment Agreement From FDA for Axpaxli Trial
Ocular Therapeutix Receives Special Protocol Assessment Agreement From FDA for Axpaxli Trial
Aug 12, 2025
07:50 AM EDT, 08/12/2025 (MT Newswires) -- Ocular Therapeutix ( OCUL ) said Monday that it has received a special protocol assessment agreement from the US Food and Drug Administration for its planned clinical trial of Axpaxli in non-proliferative diabetic retinopathy, or NPDR. This formal agreement ensures direct FDA alignment with our proposed approach for NPDR and provides us with...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Anavex Life Sciences Fiscal Q3 Loss Widens
Anavex Life Sciences Fiscal Q3 Loss Widens
Aug 12, 2025
07:48 AM EDT, 08/12/2025 (MT Newswires) -- Anavex Life Sciences ( AVXL ) reported a fiscal Q3 loss Tuesday of $0.16 per diluted share, wider than a loss of $0.14 a year earlier. Analysts polled by FactSet expected a loss of $0.14. As expected, the company did not report any revenue for the quarter. As of June 30, the company...
European Q2 corporate profit outlook improves further
European Q2 corporate profit outlook improves further
Aug 12, 2025
By Javi West Larrañaga and Marleen Kaesebier (Reuters) -The outlook for European corporate health has considerably improved, the latest earnings forecasts showed on Tuesday, showing a continued rise after the extension of the U.S.-China tariff truce and the EU-U.S. trade deal. European companies are expected to report 4.8% growth in second-quarter earnings, on average, according to LSEG I/B/E/S data. That...
Copyright 2023-2026 - www.financetom.com All Rights Reserved